Vicari G
Laboratorio di Immunologia, Istituto Superiore di Sanità, Roma.
Dev Biol Stand. 1991;75:227-32.
Viruses represent a main concern as a potential risk associated with the use of both classical biologicals and new biotechnological products. The objective of validation is to estimate quantitatively the overall level of virus clearance obtained during the various stages of purification and viral inactivation procedures. The design of a validation procedure should take into account the amount of contaminating virus in the source material, the minimum clearance factor to be attained for at least one of the stages and the minimum overall clearance factor. A major issue in performing a validation assay is in determining what viruses should be used. In addition to the inclusion of relevant viruses in the assessment, the validation should include a collection of model viruses possessing a range of biophysical and structural features and displaying a significant resistance to physical and/or chemical agents. Despite the apparent freedom from any infectious agents of source materials, such as plasma or cell lines, validation of the purification and/or inactivation procedures plays an essential and important role in establishing the safety of biologicals.
病毒是使用传统生物制品和新型生物技术产品时潜在的主要风险。验证的目的是定量评估在纯化和病毒灭活程序的各个阶段所获得的病毒清除总体水平。验证程序的设计应考虑原材料中污染病毒的数量、至少一个阶段要达到的最小清除因子以及最小总体清除因子。进行验证试验的一个主要问题是确定应使用哪些病毒。除了在评估中纳入相关病毒外,验证还应包括一系列具有生物物理和结构特征且对物理和/或化学试剂具有显著抗性的模型病毒。尽管原材料(如血浆或细胞系)表面上没有任何传染源,但纯化和/或灭活程序的验证在确保生物制品的安全性方面起着至关重要的作用。